Oncoloxía médica
Servicio
Essen University Hospital
Essen, AlemaniaPublicacións en colaboración con investigadores/as de Essen University Hospital (6)
2024
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816
2023
-
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
The Lancet, Vol. 401, Núm. 10379, pp. 821-832
-
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Targeted Oncology, Vol. 18, Núm. 5, pp. 639-641
2018
-
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 4, pp. 510-520
2017
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24